Full Text
PCN38 COST-ANALYSIS OF XELOXVS. FOLFOX-4 ± BEVACIZUMAB (BEV) IN METASTATIC COLORECTAL CANCER (MCRC) IN AN ITALIAN HOSPITAL SETTING

Abstract

Authors

LP Garrison G Giuliani P Ducournau A Cirrincione

Back to Volume 10, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×